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Abstract
Staphylococcus aureus is an important human pathogen that causes infections that may
present high morbidity and mortality. Among its many virulence factors protein A (SpA) and
Staphylococcal binding immunoglobulin protein (Sbi) bind the Fc portion of IgG interfering
with opsonophagocytosis. We have previously demonstrated that SpA interacts with the
TNF-α receptor (TNFR) 1 through each of the five IgG binding domains and induces the pro-
duction of pro-inflammatory cytokines and chemokines. The IgG binding domains of Sbi are
homologous to those of SpA, which allow us to hypothesize that Sbi might also have a role
in the inflammatory response induced by S. aureus. We demonstrate that Sbi is a novel fac-
tor that participates in the induction of the inflammatory response during staphylococcal
infections via TNFR1 and EGFR mediated signaling as well as downstream MAPKs. The
expression of Sbi significantly contributed to IL-6 production and modulated CXCL-1
expression as well as neutrophil recruitment to the site of infection, thus demonstrating for
the first time its relevance as a pro-inflammatory staphylococcal antigen in an in vivomodel.
Introduction
Staphylococcus aureus is a human pathogen that causes a wide variety of infections which in
certain cases may have high morbidity and mortality [1]. In addition to the tissue damage that
S. aureus toxins can cause in the host [1], staphylococcal infections are characterized by a pro-
found inflammatory response and very often the inflammation may account for the pathologi-
cal consequences of infection as it is the case of pneumonia, sepsis and other invasive diseases
[2]. Among the bacterial compounds that induce inflammation in the host are teichoic acids
and peptidoglycan which trigger pro-inflammatory signaling via recognition by TLR2 and
NOD receptors, respectively [3]. More recently, it has been demonstrated that protein A
induces pro-inflammatory signaling in airway epithelial and immune cells by interacting with
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the TNF-α receptor 1 (TNFR1) and the epidermal growth factor receptor (EGFR) and activat-
ing mitogen activated kinases (MAPKs) and nuclear factor κB (NF-κB) [4,5]. The interaction
between protein A and TNFR1 which involves the five conserved IgG binding domains [6] is
critical for the development of pneumonia [4].
The tremendous success of S. aureus as a pathogen is due in part to its ability to evade the
immune system through a variety of mechanisms [7–12]. Recently, the second binding protein
for immunoglobulins (Sbi) has been described as a novel evasion factor that interferes with
opsonophagocytosis and complement activity [13–16]. Sbi comprises four N-terminal globular
domains (Fig 1A). The first two N-terminal domains (I and II) are homologous to the IgG
binding domains of protein A and bind IgG of several species [15] whereas domains 3 and 4
(III and IV) which are independently folded interfere with the complement system [16]. Sbi
can be found in association with the cell envelope, where only the domains I and II are exposed
to the extracellular media, and also extracellularly as a secreted protein. Both forms of the pro-
tein contribute to immune evasion by interacting with IgG whereas only the secreted form
binds complement factor C3 [17].
The IgG binding domains I and II of Sbi have high amino acid sequence identity with each
of the corresponding domains of protein A. In particular, the amino acids involved in IgG rec-
ognition are identical or conserved (Fig 1B) [15]. Since these amino acids are required for pro-
tein A-TNFR1 and protein A-EGFR recognition [5,6], it is possible to hypothesize that Sbi may
also interact with these cellular receptors and contribute to the induction of inflammation.
Thus, this study was aimed at investigating the potential role of Sbi in the induction of inflam-
matory responses during S. aureus systemic infections.
Fig 1. Comparison of Sbi and SpA. (A) Schematic representation of Sbi and SpA domains. The IgG binding domains (grey boxes) and the complement
binding domains (black boxes) are shown. The recombinant protein Sbi (rSbi) comprising the domains I to IV was used in this study. (B) Sequence alignment
of the SpA domain B and the domains I and II of Sbi. The amino acids required for SpA-TNFR1 recognition are shown in grey.
doi:10.1371/journal.pone.0131879.g001
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Materials and Methods
Bacterial strains and growth
S. aureus (pCU1) strain Newman, the isogenic Sbi deficient mutant (Sbi-(pCU1)) [18], the Sbi-
mutant carrying a vector that restores the expression of Sbi (Sbi-(pCU1-sbi)) (constructed in
this work) and the isogenic SpA deficient mutant (SpA-) [18], were grown on tryptone soy
agar (TSA) or tryptone soy broth (TSB) at 37°C with agitation. The levels of Sbi expression in
the complemented strain were equivalent to those found in the wild type strain as compared by
RT-PCR. Antibiotics (Sigma) were added as required: chloramphenicol (Cm, 10μg/ml) (to
ensure maintenance of pCU1 plasmid), erythromycin (Em, 5 μg/ml) and kanamycin (Km,
50 μg/ml). For in vivo experiments bacteria were grown at 37°C with agitation until an OD600
of 0.8 washed and suspended in phosphate buffer (PBS). The medium generation time was
equivalent among the wild type, the Sbi- mutant and the complemented strain. Escherichia coli
BL21(DE3) was grown in Luria Bertani broth (LB) with Km at 37°C with agitation.
Cloning and expression of recombinant Sbi construct
The recombinant fragment of the N-terminal region of Sbi (amino acids 28–266) comprising
domains I, II, III and IV (Fig 1A), was engineered using genomic DNA from S. aureus strain
Newman as template. The oligonucleotides used were: 5´-ATGCAGGGATCCAAAGCGAGT
GAAAACACGCAACAAAC-3´ and 5´-AGGAGCCTCGAGTTATTACGCCACTTTCTTTT
CAGC-3´. The resulting amplified fragment was subsequently cloned into the pET-28a (+)
vector (using the incorporated BamHI and XhoI restriction sites). The presence of the cloned
fragment was confirmed by sequencing (Macrogen). The Sbi construct was expressed in E. coli
strain BL21 (DE3). Freshly transformed E. coli cells were grown until they reached an OD600 of
0.6. Isopropyl β-D-thiogalactopyranoside (SIGMA) was added to a final concentration of 1
mM and the cells were incubated at 37°C for an additional 4 h. Cells were harvested by centri-
fugation, suspended in binding buffer (20 mM Tris-HCl, 0.5 M NaCl, 10 mM imidazole, pH
8.0), and lysed by sonication. The lysate was centrifuged at 13000 rpm for 15 min and the
supernatant was recovered and stored at -80°C. The protein was purified using nickel-ion che-
lating chromatography by applying supernatant to a Ni-NTA agarose resin according the man-
ufacturer instructions (Invitrogen). The purified protein was dialyzed against PBS (Gibco) and
stored at -80°C. Potentially remaining traces of lipopolysaccharide (LPS) were removed using
Detoxi-Gel endotoxin-removing gel and columns (Pierce, Holmdel, NJ). The proteins were
proved to be free of LPS by testing of their stimulatory capacities in the presence or absence of
polymyxin B. Protein concentration was determined using a Bradford protein assay (Bio-Rad).
The resulting Mw including the 34-residue N-terminal tag
(MGSSHHHHHHSSGLVPRGSHMASMTGGQQMGR GS) was 31311.68 Da as determined
using Compute pI/Mw tool (http://web.expasy.org/compute_pi/). The protein size was con-
firmed by SDS-PAGE.
Animals and housing
Mice were obtained from the animal facility of the Department of Microbiology, School of
Medicine, University of Buenos Aires. All the procedures involving laboratory animals were
approved by the Institutional Committee for Use and Laboratory Animal Care (CICUAL) of
the School of Medicine, University of Buenos Aires (Approval number 1101) and followed
internationally accepted guidelines [19]. Animals were maintained in a conventional facility,
with controlled temperature (22 ± 1°C), controlled humidity (55%), a 12:12 hour light/dark
cycle and they were fed ad libitum. Procedures were performed in an experimental room within
Sbi Induces Inflammation
PLOS ONE | DOI:10.1371/journal.pone.0131879 June 30, 2015 3 / 14
the mouse facility. Mice were euthanized using CO2. The number of mice required for each
experiment was determined based on preliminary experiments and the desired statistical sig-
nificance. The weight of the mice used was in accordance with their age. They showed good
mobility and no differences in behavior were observed after manipulations. In this work molec-
ular markers were evaluated in live animals and postmortem. The levels of pro-inflammatory
cytokines in plasma from naïve mice were in the range of expected basal levels (IL-6: 0–50 pg/
ml; TNF-α: 0–100 pg/ml).
Primary Cultures
Peritoneal macrophages from BALB/c, C57BL/6 or TNFR1 deficient (tnfr1-/-) mice (8 to 10
weeks old, 21–23 grams) were obtained by lavaging the peritoneal cavity with RPMI1640
medium containing 10% fetal bovine serum and Penicillin (100 U/ml), Streptomycin (100 μg/
ml) and L-glutamine (2 mM) and plated in 96 well plates (4x105 cells/well) or 6 well plates
(1x106 cells/well) under the same conditions. Adherent cells were selected after 3 hours by
changing the media twice. Cells were grown for additional 20 hours prior to stimulation with
different doses of Sbi (5 and 10 μM, corresponding to 0,156 and 0.313 mg/ml). The effect of
kinase inhibitors was evaluated by pre-treating the cells with 10 μM PD98059 (MEK inhibitor
V, Calbiochem), 20 μM SB202190 (p38 MAP Kinase inhibitor II, Calbiochem) or 10 μM
AG1478 (EGFR tyrosine kinase inhibitor, Calbiochem) for 60 min and adding fresh inhibitors
during stimulation.
Mouse model
Female BALB/c mice (6 weeks old, 18–20 grams) were intraperitoneally inoculated with 200 μl
of the Sbi recombinant protein (0,075 mg/g of mice), S. aureus (pCU1), the Sbi- deficient
mutant (Sbi-pCU1) or the complemented strain (Sbi-(pCU1-sbi)) (4x107 CFU/mice). Blood
was obtained from the retro orbital sinus. Peritoneal infiltrates were obtained for cell character-
ization by flow cytometry and RNA extraction. For each in vivo determination 2–4 indepen-
dent experiments with small randomly chosen groups (control and experimental groups) of 3
to 6 animals were performed to reach the final n that is specified on each figure.
Real-time Polymerase Chain Reaction
RNA was isolated using TRIzol Reagent (Invitrogen). Complementary DNA (cDNA) was
made from 1 μg of RNA using M-MLV Reverse Transcriptase (Promega). Primers and anneal-
ing temperatures used for quantitative real-time polymerase chain reaction are listed in
Table 1. Glyceraldehyde 3-phosphate dehydrogenase (mGAPDH) was used as control for
standardization.
ELISA
IL-1β, IL-6 and TNF-α were quantified in culture supernatant and mouse serum by enzyme-
linked immunosorbent assay using matched antibody pairs (BD Biosciences).
Flow cytometry
Cells were stained with phycoerythrin-labeled anti-CD45 and fluorescein isothiocyanate-
labeled anti-Ly6G (BD Pharmingen), washed, fixed in 1% paraformaldehyde and analyzed
with a Becton Dickinson FACS Calibur. Data were collected using Cell Quest software and ana-
lyzed with Winmdi.
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Western Blot
Cells were lysed using modified RIPA buffer (50 mM Tris–HCl, 150 mMNaCl, 1 mM EDTA,
1% Triton-X-100, 1mM PMSF, 0.1% SDS, pH 7.4) containing a protease inhibitor cocktail, 1
mM sodium orthovanadate, and 1 mM sodium fluoride (Sigma-Aldrich, St. Louis, MO). Sam-
ples were incubated for 30 minutes in agitation at 4°C, centrifuged at 13000 rpm for 10 min
and the supernatant collected and stored at -80°C. Proteins were separated on 8% bis-acrylam-
ide gels, transferred to a nitrocellulose membrane, and blocked with 5% milk in TBST
(50mMTris (pH 7.5), 150 mMNaCl, and 0.05% Tween) for 1 h at room temperature. Immuno-
detection was performed using antibodies against phosphorylated extracellular signal- regu-
lated kinases 1 and 2 (phospho-erk1/2) (Santa Cruz Biotechnology, Dallas, TX), anti-phospho-
p38 (Santa Cruz Biotechnology,Dallas, TX) or actin (Sigma-Aldrich, St. Louis, MO), followed
by secondary antibodies conjugated to horseradish peroxidase (Santa Cruz Biotechnology, Dal-
las, TX). To evaluate the expression of the protein Sbi a protein A deficient mutant of S. aureus
(SpA-) was grown in TSB until an OD600 of 0.5, normal mouse serum was added to a final con-
centration of 10% V/V and the culture was grown for 2 additional hours. Independent cultures
grown without serum were used as control. Bacteria were washed with PBS, suspended in sam-
ple buffer and heated at 95°C during 10 minutes. Immunodetection was performed by over-
night incubation with a donkey anti-goat IgG conjugated to horseradish peroxidase (Santa
Cruz, sc-2020). Images were analyzed with ImageJ software.
Statistics
When comparing two groups of data Student t Test or the nonparametric Mann Whitney test
were used based on the data distribution. When comparing more than two groups of data,
parametric ANOVA and Bonferroni’s multiple comparisons post-test or Kruskal-Wallis test
and a Dunn’s post-test were used according to the data distribution. For the analysis of cyto-
kine levels in serum, Wilcoxon matched-pairs signed rank test was used. For in vivo studies
data of all the mice included in the experiments were included in the analysis. GraphPad Prism
software was used for statistical analysis.
Results
Sbi induces pro-inflammatory cytokines in macrophages via TNFR1 and
EGFR signaling
Peritoneal macrophages from BALB/c mice were stimulated with the recombinant fragment of
Sbi corresponding to domains I to IV (rSbi) for different periods of time. A significant increase
in IL-6 and TNF-α production was observed at 2 hours after stimulation (Fig 2A and 2B). IL-
1β induction was observed after 4 hours of stimulation and further increased 20 hours later
(Fig 2C). Cytokine production was not detected at earlier time points (data not shown). In
order to evaluate the potential role of TNFR1 in the initial cytokine response, peritoneal mac-
rophages from C57BL/6 or tnfr1-/-mice were stimulated with rSbi. A significant decrease in
both IL-6 and TNF-α production was observed in cells from tnfr1-/- mice compared with their
Table 1. Primers and Annealing Temperature.
Gene °C Sequence (Fw;Rev)
CXCL-1 56 50-CCGCGCCTATCGCCAATGAGCTGCGC-30; 5’-CTTGGGGACACCTTTTAGCATCTTTTGG-3'
CXCL-10 63 50-CTCTCGCAAGGACGGTCCGC-30; 50-CGTGGGCAGGATAGGCTCGG-30
GAPDH 60 50-GAAGGTGGTGAAGCAGGCAT-30; 50-TCGAAGGTGGAAGAGTGGGA-30
doi:10.1371/journal.pone.0131879.t001
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wild type controls (Fig 3A and 3B). The addition of AG1478, an inhibitor of EGFR phosphory-
lation, significantly decreased the levels of both cytokines in cells from C57BL/6 mice (Fig 3A
and 3B). Moreover, cytokine production was completely inhibited in the absence of TNFR1
and EGFR signaling as evidenced in cells from tnfr1-/- mice stimulated in the presence of
AG1478 (Fig 3A and 3B).
The signaling cascade downstream of TNFR1 and EGFR could involve the activation of
MAPKs. Thus, we next determined the ability of rSbi to activate MAPKs in macrophages. The
protein induced phosphorylation of p38 and erk1/2, which are known to positively modulate
the transcription of inflammatory cytokines, in macrophages starting at 5 min after stimulation
(Fig 3C and 3D). Phosphorylation was transient and it was not observed by 60 min of stimula-
tion (data not shown). In order to determine the importance of p-38 and erk1/2 phosphoryla-
tion in mediating the production of inflammatory cytokines in response to Sbi, peritoneal
macrophages obtained from C57BL/6 were stimulated with rSbi in the presence or absence of
specific inhibitors. The production of IL-6 was abolished in the absence of p-38 activation (Fig
3E), highlighting the importance of this MAPK in the induction of IL-6 in response to rSbi. In
addition, the erk1/2 inhibitor partially blocked the production of IL-6 indicating that this
MAPK is also involved (Fig 3E). Both, the p38 and the erk1/2 inhibitors partially inhibited
TNF-α induction in response to rSbi (Fig 3F). These results suggest that early induction of
inflammatory mediators by rSbi is mediated by TNFR1 and EGFR signaling cascades and that
Fig 2. Induction of pro-inflammatory cytokines in response to Sbi. Peritoneal macrophages obtained
from BALB/c mice were stimulated with the recombinant protein Sbi at the concentrations indicated for
different periods of time. The levels of IL-6 (A), TNF-α (B) and IL-1β (C) were quantified in the culture
supernatant by ELISA. *, P<0,05; **, P<0,01, ***, P<0,001; Student t Test.
doi:10.1371/journal.pone.0131879.g002
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Fig 3. Signaling cascades induced in response to Sbi. (A and B) Peritoneal macrophages from C57BL6
or tnfr1-/-mice were stimulated with the recombinant protein rSbi (5 μM) in the presence or absence of
AG1478, a specific EGFR phosphorylation inhibitor. (C and D) Cells were stimulated with rSbi and p-erk1/2
and p-p38 were detected at different time points by immunoblotting. Bars show the media of the densitometric
quantification of the phosphorylated species relative to actin, which was used to normalize the protein
charge, from two independent experiments. a.u., arbitrary units. (E and F) Peritoneal macrophages from
C57BL6 were stimulated with the recombinant protein rSbi in the presence or absence of specific chemical
inhibitors for p38 (SB202190) or erk1/2 (PD98059) and the levels of IL-6 and TNF-αwere quantified at two
hours after the stimulation in the culture supernatant by ELISA. Each bar represents cumulative data from 3
independent experiments. *, P<0,05; **, P<0,001; ***, P<0,0001; Student t Test.
doi:10.1371/journal.pone.0131879.g003
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the MAPKs p38 and erk1/2 are involved in this response. Similar results were obtained using
peritoneal macrophages from wild type BALB/c mice (data not shown).
Sbi induces inflammatory responses in vivo
We next evaluated the responses evoked by Sbi in vivo using a mouse model of peritoneal
inflammation. Mice were inoculated with purified rSbi (0,075 mg of protein/g of mice) by the
intraperitoneal route and the plasma levels of IL-1β, IL-6 and TNF-α were determined prior
inoculation and 2 and 4 hours thereafter. A significant increase in the circulating levels of IL-6
and TNF-α was observed at 2 hours after inoculation (Fig 4A and 4B) and both cytokines
returned to basal levels 2 hours later (data not shown). There were no significant differences in
the levels of IL-1β in plasma at all the times analyzed (data not shown). A significant increase
in the induction of the chemokines CXCL-1 and CXCL-10 was observed in mice inoculated
with rSbi compared with those inoculated with PBS (Fig 4C and 4D). These findings correlated
with a significant increase in the percentage of neutrophils recruited to the peritoneum 4 hours
after the inoculation with rSbi (Fig 4E).
We then determined the biological relevance of the above described results by using a sub-
lethal model of systemic infection. It has been demonstrated that Sbi expression is up-regulated
in the presence of human IgG [20,21]. In order to determine if this type of regulation would
occur in mice, a SpA deficient strain (SpA-) was grown in vitro in the presence of mouse
serum. A significant increase in the expression of Sbi was observed (Fig 5A) suggesting that
during in vivomouse infection the regulation of Sbi expression by serum may occur similarly
to what it has been proposed for humans. A significant increase in the circulating levels of IL-6
was observed 4 hours after inoculation with wild type S. aureus (Fig 5B and 5E) whereas the
levels of this cytokine were significantly lower in plasma from mice inoculated with the Sbi-
mutant (Fig 5C and 5E). Mice inoculated with the Sbi complemented strain showed levels of
plasmatic IL-6 equivalent to those found in mice inoculated with the wild type strain, verifying
the importance of Sbi expression in the induction of IL-6 (Fig 5D and 5E). IL-1β and TNF-α
were not detected at this time point in S. aureus inoculated mice as previously described for
this model of infection ([22] and unpublished observations). The levels of CXCL-10, signifi-
cantly increased at four hours after inoculation with S. aureus (Fig 5F). CXCL-10 was also
induced in mice inoculated with the Sbi- mutant, although the levels were lower than those
observed in mice inoculated with wild type S. aureus (Fig 5G). A significant increase in the
expression of CXCL-1 mRNA in peritoneal infiltrates was observed at two hours after inocula-
tion with S. aureus (Fig 5F). Although CXCL-1 was also induced at two hours after inoculation
with the Sbi- mutant, its expression was significantly lower than that observed in mice inocu-
lated with S. aureus (Fig 5G). The differential levels of chemokine induction in the peritoneum
evoked by the different strains correlated with significantly decreased recruitment of neutro-
phils in response to the Sbi mutant compared with the response observed in mice inoculated
with wild type S. aureus or the Sbi complemented strain (Fig 5H) demonstrating the impor-
tance of Sbi in the induction of inflammatory responses in vivo.
Discussion
S. aureus local infections are characterized by the presence of an intense inflammatory infiltrate
which may often lead to tissue damage. Similarly, the systemic inflammatory response that is
induced during S. aureus infections may conduce to the development of sepsis and shock, a
major cause of mortality. S. aureus harbors numerous components that elicit inflammatory sig-
naling cascades. In the present study, using recombinant protein as well as a set of isogenic
wild type, Sbi deficient and Sbi complemented strains, we demonstrated that Sbi is involved in
Sbi Induces Inflammation
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the production of pro-inflammatory cytokines and chemokines by macrophages as well as the
induction of neutrophil recruitment during systemic S. aureus infection.
Several receptors, including TLR2/TLR1, TLR2/TLR6, CD36, Nod proteins and TNFR1
have been implied in host recognition of structural components of S. aureus that elicit inflam-
mation [3]. Our in vitro studies using cells from mice deficient in the expression of TNFR1 or
chemical inhibition of EGFR suggest that, similar to host recognition of protein A, signaling
Fig 4. Induction of inflammatory response by Sbi in vivo.Groups of BALB/c mice were inoculated by
intraperitoneal route with PBS or rSbi (0,075 mg/g of mice). (A and B) Two hours post-inoculation, the levels
of IL–6 and TNF-α in plasma were quantified by ELISA and compared with baseline levels. **, P<0,01; ***,
P<0,001, Wilcoxon matched–pairs signed rank test. (C and D) Four hours post-inoculation the expression of
CXCL-1 and CXCL-10 was determined in cells recovered from peritoneal infiltrates and standardized to
GAPDH expression. (E) The percentage of neutrophils recruited to the peritoneumwas determined by flow
cytometry. Each circle represents a single mouse (A, B and E) or a pool of two mice (C and D) and horizontal
lines depict the median for each group. **, P< 0,01; MannWhitney non parametric test.
doi:10.1371/journal.pone.0131879.g004
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through these receptors is required for the induction of IL-6 and TNF-α by Sbi. Consistent
with TNFR1 and EGFR mediated signaling, the activation of p-38 and erk1/2 were involved in
cytokine induction. The identity of the amino acids involved in protein A-TNFR1 found in Sbi
suggest that this protein may directly interact with TNR1 and EGFR as previously demon-
strated for protein A [4–6]. However, further studies will be required to determine whether
there is a direct interaction between Sbi and TNFR1 as well as Sbi and EGFR or other accessory
molecules are involved. It is also interesting to note that although certain levels of protein A
can be found in the extracellular media the protein is mostly anchored to the cell wall [23]. Sbi,
however, lacks the typical LPXTG motif of cell wall anchored gram-positive proteins [24] and
it is found both associated to the cell membrane through interaction with lipoteichoic acids as
well as secreted into the extracellular media [17]. This would allow the protein to act on cells
that are not necessarily in close proximity to the bacteria. In fact, although protein A and Sbi
Fig 5. Contribution of Sbi to the inflammatory response induced by S. aureus during systemic infection. (A) Induction of Sbi expression in the
presence of normal mouse serum (NMS). Bars represent the media and standard deviation from three independent experiments. *, P<0.05; Student t test.
(B-H) Groups of BALB/c mice were inoculated by intraperitoneal route with PBS o 4x107 CFU of S. aureus (S. aureus (pCU1)), the Sbi deficient mutant (Sbi-
(pCU1)) or the complemented strain (Sbi- (pCU1-sbi)). (B, C and D) Four hours after the inoculation the levels of IL-6 in plasma were quantified by ELISA and
compared with baseline levels. (E) Bars represent the median for each group. (F-G) The expression of CXCL-10 and CXCL-1 was determined in cells
recovered from peritoneal infiltrates and standardized to GAPDH expression. (G) Twenty four hours post-inoculation the percentage of neutrophils recruited
to the peritoneumwas determined by flow cytometry. Each circle represents a single mouse (A, B, C, D and G) or a pool of two mice (E and F) and the
horizontal lines depict the median for each group. **, P< 0,01; Wilcoxon matched-pairs signed rank test (A, B and C). *, P< 0,05; parametric ANOVA with
Bonferroni’s multiple comparison post-test (D). *, P< 0,05; **, P< 0,01; MannWhitney non parametric test (E and F). *, P< 0,05; ***, P< 0,001 non
parametric Kruskal-Wallis with Dunn’s post-test (G).
doi:10.1371/journal.pone.0131879.g005
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seem to exploit similar signaling cascades to induce inflammation, the magnitude and the pat-
tern of the cytokine induced are not exactly the same, with Sbi inducing a much more robust
IL-6 production and a decreased induction of IL-1β than protein A in macrophages (unpub-
lished observations).
In addition to the effect of Sbi on in vitro cultured macrophages, it significantly contributed
to the elevated levels of IL-6 detected in serum during systemic S. aureus infection. The role of
IL-6 during systemic bacterial infections has been controversial with studies demonstrating
that this cytokine may play either protective or deleterious roles. Using the cecal ligation punc-
ture model of peritonitis, it has been postulated that high levels of IL-6 in the early stages of
infection are a marker for a bad prognosis for the outcome of the disease [25,26]. In this regard,
inhibition of IL-6 has showed some beneficial effects [27] although the results varied depend-
ing on the concentration of the neutralizing antibody used [28]. However, studies using IL-6
knockout mice demonstrated that a complete lack of IL-6 strongly compromised mice in sev-
eral models of infection leading to increased tissue damage and the accumulation of viable bac-
teria [29–32]. More recent work has clarified the dual role of IL-6 demonstrating that the cis-
signaling through the membrane associated IL-6 receptor is associated with the protective and
anti-inflammatory functions of the cytokine whereas the trans-signaling through the soluble
form of the receptor accomplished all the pro-inflammatory effects that lead to tissue damage
[33–38]. We have previously demonstrated a role for protein A in the induction of ADAM-17
activation and IL-6R shedding [39]. In this sense, protein A and Sbi could act synergistically to
enhance IL-6 tran-signalling. Thus, even though IL-6 is important for the resolution of the
infection, elevated levels of this cytokine are associated to exacerbated inflammatory responses,
tissue damage and organ failure. In this regard, it has been recently reported that TLR2 defi-
ciency leads to increased levels of hepatic and plasmatic IL-6 due to deregulation of IL-10 sig-
naling and that this pro-inflammatory phenotype was associated to the increased mortality
observed in TLR2 knock-out mice after systemic S. aureus challenge [40] highlighting the dele-
terious role of IL-6.
Sbi expression is highly regulated at different levels. It is negatively regulated by agr [14]
and the small RNA SprD [41] and positively regulated by saeR/S [42] and by the presence of
human IgG [20]. In the current study we demonstrated that the expression of Sbi is also
increased in the presence of mouse serum. The regulation of Sbi by serum components suggests
that this protein may be critically important during the early induction of inflammatory media-
tors after the entry of the bacteria to the bloodstream. In agreement with our findings, the
saeR/S deletion mutant induces lower levels of pro-inflammatory cytokines as compared with
the parental wild type strain in a model of peritoneal S. aureus infection [43].
It is well recognized that neutrophils are required to clear S. aureus. Nevertheless, excessive
recruitment and activation of these cells may have deleterious consequences to the host. In the
present study we demonstrate that Sbi, in addition to the induction of IL-6 also has a significant
impact in the induction of CXCL-1 at early stages during S. aureus infection as well as in the
recruitment of neutrophils to the peritoneum. Therefore, the positive contribution of Sbi to IL-
6 production and to the recruitment of neutrophils could play a deleterious role during S.
aureus infections and be a critical factor in the host outcome.
Much of the success of S. aureus as a human pathogen is due to its great ability to evoke an
exacerbated inflammatory response but also to have multiple mechanisms to evade the
immune system. As a result, the host suffers from the deleterious effects of inflammation with
poor eradication of the bacteria. The role of Sbi during immune evasion has already been pro-
posed [16,44]. In this work we demonstrate for the first time its relevance as a pro-inflamma-
tory staphylococcal antigen suggesting that Sbi is implicated in both induction of inflammation
and immune evasion.
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